Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06CTE
|
|||
| Former ID |
DAP000278
|
|||
| Drug Name |
Imiquimod
|
|||
| Synonyms |
Aldara; Beselna; Zartra; Zyclara; Imiquimod acetate; R 837; S 26308; Aldara (TN); Aldara, Imiquimod; Beselna (TN); DZ-2636; Imiquimod [USAN:INN]; MTD-39; R-837; S-26308; TMX-101; Imiquimod (JAN/USAN/INN); 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine; 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine; 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 3M Brand of Imiquimod; 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Skin cancer [ICD-11: 2C30-2C37] | Approved | [1], [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
INova Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H16N4
|
|||
| Canonical SMILES |
CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
|
|||
| InChI |
1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
|
|||
| InChIKey |
DOUYETYNHWVLEO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 99011-02-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
626307, 865810, 7740549, 8185255, 12013659, 14749564, 17396674, 17425421, 24724516, 25623636, 26752301, 26758924, 43115161, 46505394, 48426262, 49835865, 50065439, 53788646, 56313523, 57313902, 61128040, 74724996, 85174371, 87561300, 92309250, 92712277, 93167017, 99437194, 103396795, 104098475, 104312759, 117524043, 117779671, 118046220, 124757085, 124800125, 125163889, 125325444, 125360574, 126592901, 126630136, 126656817, 126670841, 127765602, 131331797, 131789979, 134337592, 135015330, 135698182, 136023845
|
|||
| ChEBI ID |
CHEBI:36704
|
|||
| ADReCS Drug ID | BADD_D01142 | |||
| SuperDrug ATC ID |
D06BB10
|
|||
| SuperDrug CAS ID |
cas=099011026
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Imiquimod (adjusted p-values: 5.79E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor 7 (TLR7) | Target Info | Agonist | [4] |
| KEGG Pathway | Toll-like receptor signaling pathway | |||
| Measles | ||||
| Influenza A | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Toll receptor signaling pathway | |||
| Reactome | Trafficking and processing of endosomal TLR | |||
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | ||||
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Toll-Like Receptors Cascades | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| Trafficking and processing of endosomal TLR | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5003). | |||
| REF 2 | New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.